Affinity Asset Advisors »

Genelux Corporation shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Genelux Corporation (GNLX) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Genelux Corporation

Tip: Access up to 7 years of quarterly data

All positions including Genelux Corporation held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Genelux Corporation by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-09-30 $237k 100k 2.37
2024-06-30 $195k 100k 1.95

More positions owned by Affinity Asset Advisors

Spdr Ser Tr S&p Biotech Put Option (XBI)
Xenon Pharmaceuticals (XENE)
Apogee Therapeutics (APGE)
Arcellx Common Stock (ACLX)
Alkermes SHS (ALKS)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Verona Pharma Sponsored Ads (VRNA)
Madrigal Pharmaceuticals (MDGL)
Crinetics Pharmaceuticals In (CRNX)
Nuvalent Inc-a (NUVL)
Spyre Therapeutics Com New (SYRE)
Wave Life Sciences SHS (WVE)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Vera Therapeutics Cl A (VERA)
Nurix Therapeutics (NRIX)

View all positions for Affinity Asset Advisors

Top funds holding Genelux Corporation

Woodward Diversified Capital
Vanguard Group
BlackRock
Geode Capital Management
Bank of America Corporation
Provident Wealth Management
Marshall Wace
Millennium Management
LPL Financial
State Street Corporation
LifeSteps Financial
Advisor Group Holdings
Amg National Trust Bank
Exchange Traded Concepts
Morgan Stanley

View all funds holding Genelux Corporation